Halozyme Therapeutics (HALO) Tops Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 --0%
EPS Growth %: +17.5%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
MOGU, JFIN, KEQU, More
EPS Growth %: +17.5%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
MOGU, JFIN, KEQU, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.02, $0.03 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $63.7 million versus the consensus estimate of $58.95 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
